Nasdaq IPOs

Imara, a Phase 2 biotech developing small molecule therapies for rare genetic disorders, raised $71 million by offering 4.5 million shares at $16, the low end of the range of $16 to $18, to command a $283 million fully diluted market cap. Imara plans to list on the Nasdaq under

DFP Healthcare Acquisitions, the second healthcare-focused blank check company formed by Deerfield Management and Robert Barasch, raised $200 million by offering 20 million units at $10. Each unit consists of one share of common stock and one-quarter of one warrant exercisable at

DFP Healthcare Acquisitions, the second healthcare-focused blank check company formed by Deerfield Management and Robert Barasch, raised $200 million by offering 20 million units at $10. Each unit consists of one share of common stock and one-quarter of one warrant exercisable at

DFP Healthcare Acquisitions, the second healthcare-focused blank check company formed by Deerfield Management and Robert Barasch, raised $200 million by offering 20 million units at $10. Each unit consists of one share of common stock and one-quarter of one warrant exercisable a

DFP Healthcare Acquisitions, the second healthcare-focused blank check company formed by Deerfield Management and Robert Barasch, raised $200 million by offering 20 million units at $10. Each unit consists of one share of common stock and one-quarter of one warrant exercisable a

We entered 2020 expecting an active IPO market from March to July, due to the depth of the pipeline and strong returns in the prior year. However, volatility from the coronavirus outbreak has now essentially shut down the spring IPO market. With admitted uncertainty, we expect a

We entered 2020 expecting an active IPO market from March to July, due to the depth of the pipeline and strong returns in the prior year. However, volatility from the coronavirus outbreak has now essentially shut down the spring IPO market. With admitted uncertainty, we expect a

We entered 2020 expecting an active IPO market from March to July, due to the depth of the pipeline and strong returns in the prior year. However, volatility from the coronavirus outbreak has now essentially shut down the spring IPO market. With admitted uncertainty, we expect a

We entered 2020 expecting an active IPO market from March to July, due to the depth of the pipeline and strong returns in the prior year. However, volatility from the coronavirus outbreak has now essentially shut down the spring IPO market. With admitted uncertainty, we expect a

We entered 2020 expecting an active IPO market from March to July, due to the depth of the pipeline and strong returns in the prior year. However, volatility from the coronavirus outbreak has now essentially shut down the spring IPO market. With admitted uncertainty, we expect

Record-high volatility and investor uncertainty have weighed on the IPO market in recent weeks, but blank check activity is as high as ever, indicating another banner year for the acquisition vehicles. So far in 2020, 19 SPACs have submitted initial filings with the SEC, a 111% i

Record-high volatility and investor uncertainty have weighed on the IPO market in recent weeks, but blank check activity is as high as ever, indicating another banner year for the acquisition vehicles. So far in 2020, 19 SPACs have submitted initial filings with the SEC, a 111% i

Record-high volatility and investor uncertainty have weighed on the IPO market in recent weeks, but blank check activity is as high as ever, indicating another banner year for the acquisition vehicles. So far in 2020, 19 SPACs have submitted initial filings with the SEC, a 111

Record-high volatility and investor uncertainty have weighed on the IPO market in recent weeks, but blank check activity is as high as ever, indicating another banner year for the acquisition vehicles. So far in 2020, 19 SPACs have submitted initial filings with the SEC, a 111

Atotech, a Carlyle-backed specialty chemicals company carved out of Total, reported financial results for the fiscal year ended December 31, 2019, in an amendment filed with the SEC on Monday. It originally filed for an IPO in January 2020 with a deal size Renaissance Capital est

Atotech, a Carlyle-backed specialty chemicals company carved out of Total, reported financial results for the fiscal year ended December 31, 2019, in an amendment filed with the SEC on Monday. It originally filed for an IPO in January 2020 with a deal size Renaissance Capital es

Atotech, a Carlyle-backed specialty chemicals company carved out of Total, reported financial results for the fiscal year ended December 31, 2019, in an amendment filed with the SEC on Monday. It originally filed for an IPO in January 2020 with a deal size Renaissance Capital es

Atotech, a Carlyle-backed specialty chemicals company carved out of Total, reported financial results for the fiscal year ended December 31, 2019, in an amendment filed with the SEC on Monday. It originally filed for an IPO in January 2020 with a deal size Renaissance Capital es

Chardan Healthcare Acquisition 2, the second blank check company formed by Chardan Capital targeting the healthcare industry, filed on Monday with the SEC to raise up to $85 million in an initial public offering. The New York, NY-based company plans to raise $85 million by offeri

Chardan Healthcare Acquisition 2, the second blank check company formed by Chardan Capital targeting the healthcare industry, filed on Monday with the SEC to raise up to $85 million in an initial public offering. The New York, NY-based company plans to raise $85 million by offer